Navigate CDx complexity to accelerate your path to regulatory approval.
In this white paper, you will learn the following:
Double Your Approval Odds: Learn how biomarker strategies can increase oncology therapeutic approval rates by twofold, as seen in 60% of 2024 FDA approvals.
Streamline CDx Development: Discovery proven strategies for selecting lab and IVD partners to accelerate development from phase 1 to market.
Navigate Complex Regulations: Gain clarity on FDA and EU IVDR requirements to ensure compliance and minimize regulatory risks.
Scott Reid, PhD, MBA, Vice President and Global Head of Companion Diagnostics at Discovery Life Sciences, brings 25 years of drug development expertise. With experience at SOPHiA Genetics and NeoGenomics, Scott leads innovative CDx solutions for global clinical trials.
Discovery Life Sciences has supported over 2,000 clinical studies, including 50+ CDx programs, leveraging cutting-edge technologies like NGS, IHC and PCR.
Ready to advance your CDx program? Schedule a consultation with our experts today.
Copyright © 2025 Discovery Life Sciences. All rights reserved.
